Masimo (MASI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
A definitive merger agreement was signed for acquisition by Danaher, with Masimo to become a wholly owned subsidiary, each share converted to $180 in cash, a 38% premium to pre-announcement price.
The board unanimously approved the merger, citing compelling value, certainty, and a thorough sale process with multiple parties contacted.
Centerview Partners provided a fairness opinion supporting the financial terms of the deal.
The merger is expected to close in the second half of 2026, subject to regulatory and shareholder approvals.
Voting matters and shareholder proposals
Shareholders will vote on the Merger Agreement Proposal and a non-binding Compensation Proposal for executive officers at a special meeting on May 1, 2026.
Approval of the merger requires a majority of outstanding shares; abstentions and broker non-votes count as votes against.
Politan Capital Management, holding 8.77% of voting power, has agreed to vote in favor of the merger.
Appraisal rights are available for dissenting shareholders under Delaware law.
Board of directors and corporate governance
The board conducted a comprehensive review of strategic alternatives, including prior sale processes and engagement with multiple potential acquirers.
The board considered risks, alternatives, and the interests of all stakeholders, including the impact on employees and ongoing litigation.
The board recommends shareholders vote FOR both proposals.
Latest events from Masimo
- Stockholders to vote on $180/share Danaher acquisition, with board unanimous support and premium offered.MASI
Proxy Filing18 Mar 2026 - $1B credit facility signed in Dec 2025 with leverage and coverage covenants, maturing 2030.MASI
Q4 202527 Feb 2026 - Masimo to be acquired by Danaher for $180 per share, pending shareholder approval.MASI
Proxy Filing17 Feb 2026 - Board approves $180/share Danaher acquisition; shareholder vote and regulatory review pending.MASI
Proxy Filing17 Feb 2026 - Shareholders will vote on a $180/share all-cash merger, with closing expected in late 2026.MASI
Proxy Filing17 Feb 2026 - Q2 revenue up 9% to $496.3M, driven by healthcare growth; non-GAAP EPS $0.86, guidance raised.MASI
Q2 20242 Feb 2026 - Stabilized growth, innovation, and a potential JV or spin-off set the stage for margin expansion.MASI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Accelerated consumer separation and margin expansion drive renewed healthcare growth focus.MASI
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Healthcare growth and margin expansion continue, with strategic options for consumer audio ongoing.MASI
2024 Wells Fargo Healthcare Conference22 Jan 2026